REGINfo: Sanofi-Aventis - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
- Remgro
- RICHEMONT
- RMB Holdings
- Sanlam
- Sasol
- Shoprite
- Standard Bank Group
- Tiger Brands
- Vodacom Group
- WOOLWORTHS
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

COMPANY SEARCH RESULT

$Sanofi-Aventis: Click to view the issuer\'s details$

Last update : 29/03/2019 >View issuer details

2019.11.25 | 18:00 | Share History / Voting Rights and Number of Shares

puce Sanofi: information concerning the total number of voting rights and shares, October 2019 - HTML (w)

2019.11.25 | 18:00 | Share History / Voting Rights and Number of Shares

puce Sanofi : informations relatives au nombre total de droits de vote et d’actions, octobre 2019 - HTML (w)

2019.11.04 | 23:30 | Permanent Information Releases / General Company News

puce Sanofi : FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older - HTML (w)

2019.11.04 | 23:30 | Permanent Information Releases / General Company News

puce Sanofi : La FDA approuve la version quadrivalente du vaccin antigrippal Fluzone® High-Dose chez l’adulte à partir de 65 ans - HTML (w)

2019.11.04 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi : Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes - HTML (w)

2019.11.04 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi : Résultats positifs de phase III pour Toujeo® dans le traitement du diabète de type 1 de l’enfant et de l’adolescent - HTML (w)

2019.10.31 | 07:30 | Periodic information / 3rd Quarter Information

puce Sanofi Q3 well on track - HTML (w)

2019.10.31 | 07:30 | Periodic information / 3rd Quarter Information

puce Troisième trimestre bien orienté pour Sanofi - HTML (w)

2019.10.31 | 04:30 | Permanent Information Releases / General Company News

puce Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation - HTML (w)

2019.10.31 | Periodic information / 3rd Quarter Information

puce Sanofi-Aventis : Third-quarter 2019 - PDF (1Mb)

2019.10.31 | Periodic information / 3rd Quarter Information

puce Sanofi-Aventis : Neuf premiers mois de 2019 - PDF (1Mb)

2019.10.29 | 13:15 | Permanent Information Releases / General Company News

puce Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis - HTML (w)

2019.10.29 | 13:15 | Permanent Information Releases / General Company News

puce Sanofi : Dupixent® (dupilumab) désormais approuvé dans l’Union européenne pour le traitement de la polypose nasosinusienne sévère - HTML (w)

2019.10.21 | 19:28 | Share History / Voting Rights and Number of Shares

puce Sanofi: information concerning the total number of voting rights and shares, September 2019 - HTML (w)

2019.10.21 | 19:28 | Share History / Voting Rights and Number of Shares

puce Sanofi : informations relatives au nombre total de droits de vote et d’actions, septembre 2019 - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 2747